Heterologous prime-boost and recombinant protein anti-TB vaccine models have shown that the vaccine-induced IL-2-secreting CD4+ T cell subsets could maintain the IL-2-producing ability for at least 26 weeks post challenge infection and were associated with enhanced control of bacterial growth in mouse models (42, 43). This evidence concerns the gene IL2 and tuberculosis.